TY - JOUR T1 - Cardiometabolic Risk Factors for COVID-19 Susceptibility and Severity: A Mendelian Randomization Analysis JF - medRxiv DO - 10.1101/2020.08.26.20182709 SP - 2020.08.26.20182709 AU - Aaron Leong AU - Joanne Cole AU - Laura N. Brenner AU - James B. Meigs AU - Jose C. Florez AU - Josep M. Mercader Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/09/01/2020.08.26.20182709.abstract N2 - Importance Early epidemiological studies report associations of diverse cardiometabolic conditions especially body mass index (BMI), with COVID-19 susceptibility and severity, but causality has not been established. Identifying causal risk factors is critical to inform preventive strategies aimed at modifying disease risk.Objective We sought to evaluate the causal associations of cardiometabolic conditions with COVID-19 susceptibility and severity.Design Two-sample Mendelian Randomization (MR) Study.Setting Population-based cohorts that contributed to the genome-wide association study (GWAS) meta-analysis by the COVID-19 Host Genetics Initiative.Participants Patients hospitalized with COVID-19 diagnosed by RNA PCR, serologic testing, or clinician diagnosis. Population controls defined as anyone who was not a case in the cohorts.Exposures Selected genetic variants associated with 17 cardiometabolic diseases, including diabetes, coronary artery disease, stroke, chronic kidney disease, and BMI, at p<5×10-8 from published largescale GWAS.Main outcomes We performed an inverse-variance weighted averages of variant-specific causal estimates for susceptibility, defined as people who tested positive for COVID-19 vs. population controls, and severity, defined as patients hospitalized with COVID-19 vs. population controls, and repeated the analysis for BMI using effect estimates from UKBB. To estimate direct and indirect causal effects of BMI through obesity-related cardiometabolic diseases, we performed pairwise multivariable MR. We used p<0.05/17 exposure/2 outcomes=0.0015 to declare statistical significance.Results Genetically increased BMI was causally associated with testing positive for COVID-19 [6,696 cases / 1,073,072 controls; p=6.7×10-4, odds ratio and 95% confidence interval 1.08 (1.03, 1.13) per kg/m2] and a higher risk of COVID-19 hospitalization [3,199 cases/897,488 controls; p=8.7×10-4, 1.12 (1.04, 1.21) per kg/m2]. In the multivariable MR, the direct effect of BMI was abolished upon conditioning on the effect on type 2 diabetes but persisted when conditioning on the effects on coronary artery disease, stroke, chronic kidney disease, and c-reactive protein. No other cardiometabolic exposures tested were associated with a higher risk of poorer COVID-19 outcomes.Conclusions and Relevance Genetic evidence supports BMI as a causal risk factor for COVID-19 susceptibility and severity. This relationship may be mediated via type 2 diabetes. Obesity may have amplified the disease burden of the COVID-19 pandemic either single-handedly or through its metabolic consequences.Question Is there a causal association between cardiometabolic conditions and COVID-19 susceptibility or severity?Findings Using two-sample Mendelian randomization of 17 cardiometabolic diseases and traits, only body mass index was found to be causally associated with testing positive for COVID-19 (6,696 cases/ 1,073,072 controls; p=6.7×10-4) and a higher risk of COVID-19 (3,199 cases/897,488 controls; p=8.7×10-4).Meaning Genetic evidence supports BMI as a causal risk factor for COVID-19 susceptibility and severity.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe project was partly supported by American Diabetes Association grant #7-20-COVID-003 and the American Diabetes Association Innovative and Clinical Translational Award 1-19-ICTS-068. JBC is supported by American Diabetes Association Postdoctoral Fellowship 1-19-PDF-028. AL is supported by Grant 2020096 from the Doris Duke Charitable Foundation. LB is partially supported by Apple Inc. JBM is supported by R01DK078616, U01DK078616 and R01HL151855. JCF is supported by NIDDK K24 DK110550. The funders played no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All analyses were conducted using summary associations statistics, no individual level data requiring IRB approval was used. No approval from the IRB/oversight body was required.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the results from this study are presented in the manuscript and online supplement. All datasets used to generate results are publicly available. ER -